Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Nitric oxide for the evaluation and treatment of pulmonary hypertension in congenital heart disease.

Literature DB >> 9456484

Nitric oxide for the evaluation and treatment of pulmonary hypertension in congenital heart disease.

J P Kovalchin¹, A R Mott, K L Rosen, T F Feltes.

Abstract

The use of inhaled nitric oxide as a selective pulmonary vasodilator has expanded to include patients with congenital heart disease and pulmonary hypertension. The therapeutic and diagnostic roles of inhaled nitric oxide offer additional alternatives and benefits to these patients with pulmonary hypertension, particularly in the postoperative setting. This article reviews the background, mechanism of action, toxicities, and current clinical applications of inhaled nitric oxide in the child with congenital heart disease and pulmonary hypertension.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1997 PMID： 9456484 PMCID： PMC325473

Source DB: PubMed Journal: Tex Heart Inst J ISSN： 0730-2347

65 in total

1. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase.

Authors: S L Archer; J M Huang; V Hampl; D P Nelson; P J Shultz; E K Weir
Journal: Proc Natl Acad Sci U S A Date: 1994-08-02 Impact factor: 11.205

2. Negative feedback regulation of endothelial cell function by nitric oxide.

Authors: G M Buga; J M Griscavage; N E Rogers; L J Ignarro
Journal: Circ Res Date: 1993-11 Impact factor: 17.367

Review 3. Selectins.

Authors: M P Bevilacqua; R M Nelson
Journal: J Clin Invest Date: 1993-02 Impact factor: 14.808

4. Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome.

Authors: H Gerlach; R Rossaint; D Pappert; K J Falke
Journal: Eur J Clin Invest Date: 1993-08 Impact factor: 4.686

5. Pulmonary vasodilatory effects of 12 and 60 parts per million inhaled nitric oxide in children with ventricular septal defect.

Authors: R W Day; J M Lynch; R E Shaddy; G S Orsmond
Journal: Am J Cardiol Date: 1995-01-15 Impact factor: 2.778

Review 6. Nitric oxide and nitrovasodilators: similarities, differences and potential interactions.

Authors: T J Anderson; I T Meredith; P Ganz; A P Selwyn; A C Yeung
Journal: J Am Coll Cardiol Date: 1994-08 Impact factor: 24.094

7. L-arginine infusion has no effect on systemic haemodynamics in normal volunteers, or systemic and pulmonary haemodynamics in patients with elevated pulmonary vascular resistance.

Authors: S V Baudouin; P Bath; J F Martin; R Du Bois; T W Evans
Journal: Br J Clin Pharmacol Date: 1993-07 Impact factor: 4.335

8. Continuous nitric oxide inhalation reduces pulmonary arterial structural changes, right ventricular hypertrophy, and growth retardation in the hypoxic newborn rat.

Authors: J D Roberts; C T Roberts; R C Jones; W M Zapol; K D Bloch
Journal: Circ Res Date: 1995-02 Impact factor: 17.367

3. Development of advanced pulmonary vascular disease in D-transposition of the great arteries after the neonatal arterial switch operation.

Authors: S M Rivenes; R G Grifka; T F Feltes
Journal: Tex Heart Inst J Date: 1998

Review 4. Role of oxidized lipids in pulmonary arterial hypertension.

Authors: Salil Sharma; Grégoire Ruffenach; Soban Umar; Negar Motayagheni; Srinivasa T Reddy; Mansoureh Eghbali
Journal: Pulm Circ Date: 2016-09 Impact factor: 3.017

4 in total